$CLYM stock has now fallen 8% today, according to our price data from Polygon. There has been approximately $1,623,728 of trading volume.
Here is what we see in our data on $CLYM (you can track the company live on Quiver's $CLYM stock page):
$CLYM Insider Trading Activity
$CLYM insiders have traded $CLYM stock on the open market 7 times in the past 6 months. Of those trades, 3 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $CLYM stock by insiders over the last 6 months:
- STEPHEN BASIL THOMAS has made 0 purchases and 4 sales selling 150,000 shares for an estimated $879,381.
- CAPITAL MANAGEMENT, L.P. RA has made 3 purchases buying 321,672 shares for an estimated $779,625 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CLYM Hedge Fund Activity
We have seen 34 institutional investors add shares of $CLYM stock to their portfolio, and 38 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. removed 20,125,439 shares (-64.1%) from their portfolio in Q4 2025, for an estimated $80,501,756
- MPM BIOIMPACT LLC added 2,671,480 shares (+inf%) to their portfolio in Q4 2025, for an estimated $10,685,920
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,396,722 shares (+265.1%) to their portfolio in Q4 2025, for an estimated $5,586,888
- ADAR1 CAPITAL MANAGEMENT, LLC added 1,298,945 shares (+972.8%) to their portfolio in Q4 2025, for an estimated $5,195,780
- TANG CAPITAL MANAGEMENT LLC removed 1,000,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $4,000,000
- GREAT POINT PARTNERS LLC added 979,534 shares (+inf%) to their portfolio in Q4 2025, for an estimated $3,918,136
- POINT72 ASSET MANAGEMENT, L.P. added 716,680 shares (+inf%) to their portfolio in Q4 2025, for an estimated $2,866,720
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CLYM Analyst Ratings
Wall Street analysts have issued reports on $CLYM in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 02/13/2026
- HC Wainwright & Co. issued a "Buy" rating on 12/18/2025
- William Blair issued a "Outperform" rating on 10/16/2025
To track analyst ratings and price targets for $CLYM, check out Quiver Quantitative's $CLYM forecast page.
$CLYM Price Targets
Multiple analysts have issued price targets for $CLYM recently. We have seen 8 analysts offer price targets for $CLYM in the last 6 months, with a median target of $16.0.
Here are some recent targets:
- Mayank Mamtani from B. Riley Securities set a target price of $26.0 on 03/24/2026
- Danielle Brill from Truist Securities set a target price of $17.0 on 03/18/2026
- Christopher Raymond from Raymond James set a target price of $25.0 on 03/11/2026
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $15.0 on 03/10/2026
- Laura Chico from Wedbush set a target price of $14.0 on 03/06/2026
- Colleen Kusy from Baird set a target price of $12.0 on 03/06/2026
- Yasmeen Rahimi from Piper Sandler set a target price of $23.0 on 02/13/2026
You can track data on $CLYM on Quiver Quantitative.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
